The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
Rangelova, E; Stoop, T F; van Ramshorst, T M E; Ali, M; van Bodegraven, E A; Javed, A A; Hashimoto, D; Steyerberg, E; Banerjee, A; Jain, A; Sauvanet, A; Serrablo, A; Giani, A; Giardino, A; Zerbi, A; Arshad, A; Wijma, A G; Coratti, A; Zironda, A; Socratous, A; Rojas, A; Halimi, A; Ejaz, A; Oba, A; Patel, B Y; Björnsson, B; Reames, B N; Tingstedt, B; Goh, B K P; Payá-Llorente, C; Domingo Del Pozo, C; González-Abós, C; Medin, C; van Eijck, C H J; de Ponthaud, C; Takishita, C; Schwabl, C; Månsson, C; Ricci, C; Thiels, C A; Douchi, D; Hughes, D L; Kilburn, D; Flanking, D; Kleive, D; Sousa Silva, D; Edil, B H; Pando, E; Moltzer, E; Kauffman, E F; Warren, E; Bozkurt, E; Sparrelid, E; Thoma, E; Verkolf, E; Ausania, F; Giannone, F; Hüttner, F J; Burdio, F; Souche, F R; Berrevoet, F; Daams, F; Motoi, F; Saliba, G; Kazemier, G; Roeyen, G; Nappo, G; Butturini, G; Ferrari, G; Kito Fusai, G; Honda, G; Sergeant, G; Karteszi, H; Takami, H; Suto, H; Matsumoto, I; Mora-Oliver, I; Frigerio, I; Fabre, J M; Chen, J; Sham, J G; Davide, J; Urdzik, J; de Martino, J; Nielsen, K; Okano, K; Kamei, K; Okada, K; Tanaka, K; Labori, K J; Goodsell, K E; Alberici, L; Webber, L; Kirkov, L; de Franco, L; Miyashita, M; Maglione, M; Gramellini, M; Ramera, M; João Amaral, M; Ramaekers, M; Truty, M J; van Dam, M A; Stommel, M W J; Petrikowski, M; Imamura, M; Hayashi, M; D'Hondt, M; Brunner, M; Hogg, M E; Zhang, C; Ángel Suárez-Muñoz, M; Luyer, M D; Unno, M; Mizuma, M; Janot, M; Sahakyan, M A; Jamieson, N B; Busch, O R; Bilge, O; Belyaev, O; Franklin, O; Sánchez-Velázquez, P; Pessaux, P; Strandberg Holka, P; Ghorbani, P; Casadei, R; Sartoris, R; Schulick, R D; Grützmann, R; Sutcliffe, R; Mata, R; Patel, R B; Takahashi, R; Rodriguez Franco, S; Sánchez Cabús, S; Hirano, S; Gaujoux, S; Festen, S; Kozono, S; Maithel, S K; Chai, S M; Yamaki, S; van Laarhoven, S; Mieog, J S D; Murakami, T; Codjia, T; Sumiyoshi, T; Karsten, T M; Nakamura, T; Sugawara, T; Boggi, U; Hartman, V; de Meijer, V E; Bartholomä, W; Kwon, W; Koh, Y X; Cho, Y; Takeyama, Y; Inoue, Y; Nagakawa, Y; Kawamoto, Y; Ome, Y; Soonawalla, Z; Uemura, K; Wolfgang, C L; Jang, J Y; Padbury, R; Satoi, S; Messersmith, W; Wilmink, J W; Abu Hilal, M; Besselink, M G; Del Chiaro, M; ,
PURPOSE/OBJECTIVE:To assess the association between neoadjuvant therapy and overall survival (OS) in patients with left-sided resectable pancreatic cancer (RPC) compared to upfront surgery. BACKGROUND:Left-sided pancreatic cancer is associated with worse OS compared to right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with RPC, current randomized trials included mostly patients with right-sided RPC. METHODS:International multicenter retrospective study including consecutive patients after left-sided pancreatic resection for pathology-proven RPC, either after neoadjuvant therapy or upfront surgery in 76 centers from 18 countries on 4 continents (2013-2019). Primary endpoint is OS from diagnosis. Time-dependent Cox regression analysis was performed to investigate the association of neoadjuvant therapy with OS, adjusting for confounders at time of diagnosis. Adjusted OS probabilities were calculated. RESULTS:=0.96) involvement. CONCLUSIONS:Neoadjuvant therapy in patients with left-sided RPC was associated with improved OS compared to upfront surgery. The impact of neoadjuvant therapy increased with larger tumor size and higher serum CA19-9 at diagnosis. Randomized controlled trials on neoadjuvant therapy specifically in patients with left-sided RPC are needed.
PMID: 39814200
ISSN: 1569-8041
CID: 5776932